Abstract The 11th Acromegaly Consensus Conference in April 2017 was convened to
update recommendations on therapeutic outcomes for patients with acromegaly. Consensus …

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of
diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Pituitary adenomas are one of the most common primary central nervous system tumors and
have an estimated prevalence of 17%. Approximately half of pituitary adenomas secrete …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

The classification of adenohypophysial neoplasms as “pituitary neuroendocrine
tumors”(PitNETs) was proposed in 2017 to reflect their characteristics as epithelial …

Background Despite the substantial impact of cavernous sinus invasion (CSI) in pituitary
adenoma surgery, its radiologic determination has been inconsistent and variable, and the …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …

BACKGROUND: Several studies report early results of endoscopic endonasal
transsphenoidal surgery; however, none discuss long-term outcome measures such as …

Acromegaly (ACM) is a chronic, progressive disorder caused by the persistent
hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The …